TransCode Therapeutics

(NASDAQ) RNAZ

Current Price$5.49

Market Cap$5.07M

Since IPO (2021)-100%

5 YearN/A

1 Year-26%

1 Month-24%

TransCode Therapeutics Financials at a Glance

Market Cap

$5.07M

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.36M

EPS (TTM)

-$48.65

P/E Ratio

-0.11

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$5.49

Volume

308

Open

$5.49

Price

$5.49

Volume

308

Open

$5.49

Previous Close

$5.49

Daily Range

$5.49 - $5.49

52-Week Range

$3.82 - $20.99

Estimated Earnings Date

Aug 18, 2026

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$5.49

Volume

308

Open

$5.49

Previous Close

$5.49

Daily Range

$5.49 - $5.49

52-Week Range

$3.82 - $20.99

Estimated Earnings Date

Aug 18, 2026

RNAZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TransCode Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Philippe P. Calais, PhD

Website

www.transcodetherapeutics.com

Headquarters

Boston, MA 02109, US

RNAZ Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-52%

Return on Capital

-21%

Return on Assets

-26%

Earnings Yield

-9.09%

Dividend Yield

0.00%

Payout Ratio

-42.75%

Stock Overview

Market Cap

$5.07M

Shares Outstanding

950.30K

Volume

308

Avg. Volume

49.84K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$27.98M

EBITDA

-$34.31M

Operating Cash Flow

-$19.52M

Capital Expenditure

-$6.66K

Free Cash Flow

-$19.52M

Cash & ST Invst.

$17.81M

Total Debt

$0.00

TransCode Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$23.94K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.07M

N/A

Market Cap/Employee

$723.59K

N/A

Employees

N/A

Net Income

-$17.79M

-47.2%

EBITDA

-$17.53M

-45.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$12.84M

+10.9%

Total Debt

$0.00

N/A

Accounts Receivable

$2.30M

+612.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-25.68%

N/A

Return on Invested Capital

-21.17%

N/A

Free Cash Flow

-$4.98B

-160638.4%

Operating Cash Flow

-$4.98B

-160638.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

APREAprea Therapeutics, Inc.

APREAprea Therapeutics, Inc.$0.69-10.31%

INABIN8bio, Inc.

INABIN8bio, Inc.$1.43-0.69%

HCWBHCW Biologics Inc.

HCWBHCW Biologics Inc.$1.28-3.03%

ACXPAcurx Pharmaceuticals, Inc.

ACXPAcurx Pharmaceuticals, Inc.$1.57-4.85%

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$4.56-4.40%

LYRALyra Therapeutics, Inc.

LYRALyra Therapeutics, Inc.$0.44-11.98%

APVOAptevo Therapeutics Inc.

APVOAptevo Therapeutics Inc.$4.78-1.65%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

Questions About RNAZ

What is the current price of TransCode Therapeutics?

TransCode Therapeutics is trading at $5.49 per share.

What is the 52-week range for TransCode Therapeutics?

Over the past 52 weeks, TransCode Therapeutics has traded between $3.82 and $20.99.

How much debt does TransCode Therapeutics have?

As of the most recent reporting period, TransCode Therapeutics reported total debt of $0.00.

How much cash does TransCode Therapeutics have on hand?

TransCode Therapeutics reported $12.84M in cash and cash equivalents in its most recent financial results.

What is TransCode Therapeutics’s dividend yield?

TransCode Therapeutics does not currently have a dividend yield.

TransCode Therapeutics

TransCode Therapeutics Financials at a Glance

RNAZ News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About TransCode Therapeutics

RNAZ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

TransCode Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RNAZ

What is the current price of TransCode Therapeutics?

What is the 52-week range for TransCode Therapeutics?

How much debt does TransCode Therapeutics have?

How much cash does TransCode Therapeutics have on hand?

What is TransCode Therapeutics’s dividend yield?

Premium Investing Services